Exendin-4 significantly increased insulin level and phosphorylation of insulin receptor substrate 1 (IRS-1) in rat hippocampus, and could not change the status of tau phosphorylation without insulin in HT22 neurons, suggesting that insulin is required in reduction of tau hyperphosphorylation by GLP-1R agonists (154)
However, its a stimulant that can be habit-forming
Current FDA-approved GLP-1 drugs available on the market include: Byetta (exenatide) Foundayo (orforglipron) Trulicity (dulaglutide), Victoza, Saxenda, Xultophy (liraglutide) Ozempic, Rybelsus, Wegovy (semaglutide) Mounjaro, Zepbound (tirzepatide) While all GLP-1 drugs can cause weight loss as a side effect, only Wegovy, Saxenda, Foundayo, and Zepbound are FDA approved for weight loss
The queries for the articles about the gut-liver axis: ((GLP-1RAs[Title/Abstract]) OR (GLP-1R agonists[Title/Abstract]) OR (GLP-1 receptor agonists[Title/Abstract]) OR (GLP-1 receptor[Title/Abstract])) AND ((liver[Title/Abstract]) OR (hepatic[Title/Abstract]) OR (HCC[Title/Abstract])) AND (microbiota[Title/Abstract])
Metabolic syndrome and related disorders
Improved Quality of Life By managing blood sugar levels and promoting weight loss, Semaglutide can significantly improve overall quality of life
